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Fc receptors for IgG (FcyR) on macrophages, polymorphonuclear leukocytes,
and B and T lymphocytes perform a central role in immune defenses since these
receptors link the humoral and cellular effector limbs of the immune system and
thus confer an element of humoral specificity on the effector cells that bear
FcyR . Recently, two murine FcyR genes, a and #, have been cloned and
sequenced (1-3) . Transfection of the )3 gene into melanoma cells results in the
appearance, on the cell surface, of the epitope recognized by mAb 2AG2, an
anti-FcyR mAb (4, 5), and the FcyR binding activity . Both the a and # genes
encode proteins containing a leader sequence, NH2-terminal extracellular do-
mains, one putative transmembranespanning domain, andacytoplasmic domain .
The two genes are 95% homologous in the extracellular domains, which consist
of two repeats of 85 amino acids. Moreover, these domains bear significant
homology to other members of the Ig gene superfamily, with the most striking
similarity found between the #2 domain of mouse ER and the most distal NH2-
terminal domain of the FcyR .
To make the secreted form of an FcyR, the coding sequence for the trans-
membrane and cytoplasmic domains of FcyR# was deleted from the cDNA, and
a termination codon wasintroduced . This truncated FcyR#cDNA in a eukaryotic
expression vector was then transfected into a dihydrofolate reductase (DHFR)'-
negative CHO line along with a dhfr minigene . Production of the truncated
FcyR# was then amplified by addition of methotrexate in medium . Theresulting
cell line secretes 2-3 Ag/ml/d of truncated FcyR# . The availability of large
quantities ofpurified receptor has facilitatedexaminationof theternary structure
of the protein and allowed us to confirm the membrane orientation and to map
an epitope recognized by an anti-FcyR mAb, 6B7C .
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Materials and Methods
Cell Culture.
￿
Unless otherwise specified, chemicals were obtained from Sigma Chem-
ical Co . (St. Louis, MO). The CHO mutant cell line DG44, which has a deletion of the
DHFR gene (6), was provided by Dr . Chasin (Columbia University, New York, NY), and
wasmaintained in DME(Gibco Laboratories, Grand Island, NY)supplemented with 0.016
This work was supported by U.S . Public Health Service grants AI-24322 U . C. Unkeless) and DK-
10080 U . D. Glass) .
'Abbreviations used in this paper:
￿
DHFR, dihydrofolate reductase ; HRP, horseradish peroxidase ;
TBS, Tris-buffered saline ; sulfo-MBS, sulfo-m-maleimidobenzoyl-N-hydroxysuccinimide .
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mM thymidine, 0.1 mM hypoxanthine, 0.3 mM proline, and 10% FCS (Flow Laboratories
Inc., McLean, VA). Hypoxanthine was omitted and dialyzed FCS was used in medium for
selection of transfectants. The 549.1 cell line was grown in suspension culture in «-MEM
(Gibco Laboratories) supplemented with 5% FCS. In some experiments, cells were
cultured in serum-free medium, supplemented with a hormone mixture containing
transferrin (5 wg/ml), epidermal growth factor (50 ng/ml), bovine insulin (10 Ag/ml),
glucagon (1 ng/ml), somatotropin (6.5 ng/ml), and hydrocortisone (3 .5 AM) (7). Secretory
products of transfected and amplified CHO cell lines were biosynthetically labeled with
[s5S]methionine (1,100 Ci/mol; Amersham Corp., Arlington Heights, IL) in methionine-
free medium supplemented with hormones.
Monoclonal Antibodies.
￿
The antidinitrophenyl (DNP) mAbs DHK10.12 (IgG2b) and
DH K109.3 (IgGI) were a generous gift of Dr. Schlessinger (Washington University, St.
Louis, MO); U12 .5 (IgG2b), U7 .27 (IgG2a), and U7.6 (IgGI) were the kind gift of Dr.
Eschar (Weitzmann Institute, Rechovot, Israel). The myeloma protein MPC-11 (IgG2b)
was a gift of Dr. Eisen (Massachusetts Institute of Technology, Cambridge, MA). The
anti-DNP mAbs were purified from conditioned medium by affinity chromatography on
a TNP25BSA Sepharose-4B column, and the bound mAb was eluted with 0.1 M DNP,
0.1 M Tris-HCl, pH 8.0. The DNP was removed by gel filtration on Sephadex G-25 .
Plasmidconstruction.
￿
The enzymes used were purchased from New England Biolabs
(Beverly, MA) unless otherwise indicated. Calf intestine alkaline phosphatase was from
Boehringer Mannheim Biochemicals (Indianapolis, IN) . The methods used for construc-
tion of expression vector were based on those of Maniatis et al . (8). Plasmid 3901, a ,0,
cDNA clone (1), was restricted by Apa I at base 947 within the insert and the resulting 3'
overhang was blunted by T4 DNA polymerase. The unique Apa I restriction site is 26 by
upstream of the transmembrane encoding region and results in deletion of the transmem-
brane and cytoplasmic domains, leaving a 172-amino acid protein that contains the two
extracellular Ig-like domains (see Fig. 1). The stop codon was introduced into the reading
frame by ligation of the phosphorylated 16-bp universal terminator, GCTTAATTAAT-
TAAGC (Pharmacia Fine Chemicals, Piscataway, NJ), to the termini of the linearized
plasmid. This results in addition of four accessory amino acid residues, GLIN, before the
termination codon is reached. Next, Nco I was used to cut the cDNA at base 338, one
base pair before the first methionine codon of the translated sequence. After Hha I
digestion to remove concatamerized terminators, the overhangs generated by those two
enzymes were blunted by incubation with DNA polymerase Klenow fragment. The 620-
bp DNA fragment between Apa I and Nco I restriction sites with the ligated terminator
at the 3' end was isolated by preparative agarose gel electrophoresis and ligated into the
Sma I restriction site of linearized dephosphorylated pcEXV-3 expression vector (9). The
truncated cDNA insert is predicted to encode a protein with 176 amino acid residues.
Two plasmids, pFc-yR,8-19 (Fig. 1) and pFcyR/3-17, which contain the inserts with sense
and antisense orientations, respectively, were obtained after transformation of MM294.
Transfection ofCHO Cell Line and Amplification.
￿
The CHO-derived cell line DG44 was
seeded at 4 x 105 cells per 100-mm dish and cultured overnight. The cells were
cotransfected by incubation with a DNA-calcium phosphate precipitate containing pMG 1
(0.1 Ag per plate), which is the dhfr minigene construct (10), given to us by Dr. Chasin
(Columbia University), the FcyR,B cDNA construct (2 Ag per plate), and carrier DNA (20
I.Lg per plate) as described by Wigler et al. (11). After 2 d, the cells were subcultured and
the transfected cells were selected in medium'w;thout hypoxanthine containing 10%
dialyzed FCS. After 2 wk, 0 .02 AM methotrexate was added to the medium followed by
stepwise increments every 10 d to 0.05, 0.1, 1 .0, and 2.0 AM methotrexate (12). The cells
were then cloned and clones were screened for secretion of Fc7R,8. The cultures were
then maintained routinely in the presence of 2.0 AM methotrexate.
Immunoassays for FcyR,B (ELISA).
￿
FcyR,B in cell culture medium or purified FcyRO
was titered by a modification of the monoclonal sandwich radioimmune assay described
previously (13). FcyR in assay samples was adsorbed onto flat-bottomed wells (Immulon-
2; Dynatech Laboratories Inc., Alexandria, VA) previously coated overnight with rabbit
anti-FcyR IgG (5 ug/ml) in PBS and blocked with 3% BSA. FcyR,B was detected byQU ET AL.
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sequential addition of the rat anti-FcyR mAb 2AG2 (5 jig/ml in PBS), biotinylated goat
anti-rat IgG antibody (0.5 rig/ml) (Kirkegaard & Perry Laboratories, Inc., Gaithersburg,
MD) and streptavidin-horse radish peroxidase (HRP) (0.5 ag/ml) (Kirkegaard & Perry,
Inc.), and developed as described (14). The assay was calibrated by inclusion ofa detergent
lysate of S49.1 cells (1% NP-40 in PBS, 10' cells/ml).
A similar protocol was used to analyze the binding of the rat anti-FcyR mAbs 2AG2
and 6B7C to flat-bottomed plates coated with OVA or a peptide-OVA conjugate.
Cytoplasmic RNA Dot Hybridization. Preparations of cytoplasmic RNA from tissue
culture cells and dot blots were as described by White and Bancroft (15). Prehybridization
and hybridization of blots with probes labeled with a-["P]CTP (3,000 Ci/mmol; Amer-
sham Corp.) by nick translation were carried out as described by Dobner et al. (16). The
probes were the FcyR# cDNA insert of pFcyR#-17 and the rat metallothionein 1 cDNA
insert of plasmid p2A10 (17), kindly donated by Dr. Bancroft (Mount Sinai School of
Medicine, New York, NY).
Purification of Truncated FcyR#.
￿
Cell culture supernatant containing 5 or 10% FCS
was collected and protein precipitated between 40-75% ammonium sulfate saturation was
collected by centrifugation. The protein was redissolved in a minimal volume of sodium
phosphate buffer (10 mM, pH 7.5) and dialyzed against the same buffer. The truncated
FcyR# was isolated by passing the concentrated protein solution over a DHK10.12
(IgG2bK) Sepharose-4B (Pharmacia Fine Chemicals)affinity column (5-10 mg protein/ml
bed volume), which was then washed with sodium phosphate buffer (10 mM, pH 7 .5)
containing 50 mM NaCl until the OD2ao returned to baseline. The bound truncated
FcyR# was eluted with sodium acetate buffer (0.1 M, pH 4) containing0.5 M NaCl, and
dialyzed versus PBS. The protein at this stage wasjudged pure by SDS-PAGE.
SDS-PAGE andImmunoblotting.
￿
SDS-PAGE was performed using Neville buffers (18)
on slab gels. For immunoblotting (19), nonreduced protein samples were subjected to
SDS-PAGE and transferred to nitrocellulose (Bio-Rad Laboratories, Richmond, CA) with
a nonbuffer tank electroblotter (Polyblot; American Bionetics, Emeryville, CA) as the
manufacturer recommended. After the nonspecific sites were blocked in Tris-buffered
saline (TBS) containing3% BSA, the nitrocellulose was incubated with preimmune rabbit
antibodies, rabbit anti-FcyR IgG or rat anti-FcyR mAb 6B7C (20 hg/ml in TBS with 1
BSA) on a miniblotter (Miniblotter II ; Immunetics, Cambridge, MA), followed by bioti-
nylated goat anti-rabbit and goat anti-rat IgG (0 .5 ag/ml each) and streptavidin-conju-
gated HRP (0.5 Ag/ml). The bound HRP was visualized with 4-chloro-l-napthol (20).
Assay of Binding of Immune Complexes by Truncated FcyR#.
￿
Crystallized BSA was
derivatized with DNP groups by reaction with dinitrobenzene sulfonic acid (Pierce
Chemical Co., Rockford, IL) in 2% Na2COs, and after gel filtration, the extent of
substitution was determined as described previously (21). The DNP2oBSA (50 tig) was
then radiolabeled with 1 mCi ofcarrier-free Na[1251] (Amersham Corp.) using tubes coated
with 1 wg of iodogen (Pierce Chemical Co.) (22). Unincorporated 1251 was removed by gel
filtration on a G-25M column. The labeled protein had the sp act of 1 .25 X 10' cpm/wg.
Flexible 96-well U-bottomed plates (Micro-2000; Dynatech Laboratories, Inc.) were
coated with purified truncated FcyR# (5 wg/ml in PBS) at 4°C overnight and the wells
were quenched by 3% nonfat dry milk in PBS at room temperature for 2 h. Immune
complexes were formed by incubation of serial twofold dilutions of different anti-DNP
mAbs with [ 1251]DNP2oBSA in 0.2X PBS at room temperature for 2 h and the complexes
were then transferred to the FcyR#-coated wells. After further incubation a"t room
temperature for 2 h, the plates were rapidly rinsed in 10 mM phosphate buffer (pH 7.5).
The wells were cut out and radioactivity was measured by gamma counter (1217 Ria-
Gamma; LKB-Wallac, Turku, Finland).
Peptide Synthesis and Conjugation.
￿
The peptide ITVQGPKSSRSLPVL, residues 169-
183 of FcyR#, was synthesized stepwise by solid-phase methods on an automated peptide
synthesizer (model 9500; Biosearch, San Rafael, CA). A cysteamine residue was attached
to the resin through a thioether linkage before start of automated synthesis (23). After
deblocking, this results in a COOH-terminal sulfbydryl group for derivatization. The1198
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peptide was purified by reverse-phase chromatography on a Vydac C-18 HPLC column.
Amino acid analysis after hydrolysis was consistent with the sequence.
Since the peptide contained a free sulfhydryl group, the bifunctional reagent sulfo-m-
maleimidobenzoyl-N-hydroxysuccinimide ester (sulfo-MBS) (Pierce Chemical Co.) was
used to make the peptide-protein conjugate, as described by Youle and Neville (24).
Briefly, 5 mg of OVA was dissolved in 0 .5 ml of sodium phosphate buffer (10 mM, pH
7.5) and mixed with 0.5 mg of sulfo-MBS in 10 Al of dimethylformamide by vortexing.
The molar ratio of sulfo-MBS to OVA was 8.7:1 . After incubation at room temperature
for 30 min, the acylated OVA was desalted over a Sephadex G-25M column (Pharmacia
Fine Chemicals) in 10 mM phosphate buffer (pH 7.5) with 15 mM NaCl . The protein was
then incubated with 1 mg of peptide in 2 ml of same buffer at room temperature for 2 h.
The molar ratio of peptide to OVA was 5.2:1 . The peptide-OVA conjugate,
ITVQGPKSSRSLPVL-OVA,was then filtered through a small Sephadex G-25M column.
Disulfide Analysis.
￿
Ellman's reagent (25), 5,5'-dithio-bis(2-nitrobenzoic acid) (Calbi-
ochem-Behring Corp., La Jolla, CA) was used to titrate the number of sulfhydryl groups
in the truncated FcyRj6 as described by Anderson and Wetlaufer (26) for peptides. Protein
dissolved in 0.1 M acetic acid and 0.2% SDS (0.25 ml) was mixed with an equal volume
of 6 N NaOH and boiled for 5 min or incubated at 37°C overnight. The alkaline solution
was neutralized by the addition of 0.5 ml of 6 N H3P04 containing 2 mM EDTA. 100 A1
of the Ellman's reagent (1 mg/ml in 20 mM sodium acetate buffer, pH 5.5, with 1 mM
EDTA) was then added into the neutralized solution, and the absorbance at 412 nm, due
to the release of 2-nitro-5-thiobenzoic acid, was measured. The concentration of free
sulfhydryl groups was calculated from the extinction coefficient of 13,600/M/cm (25).
Crystallized BSA was used to determine the yield of free -SH groups per disulfide bond
following alkaline cleavage. The yield of -SH/S-S experimentally determined for BSA
(1 .31, see Table 11) agrees well with the value determined for model peptides (e.g., 1 .34
for oxidized glutathione) (26).
Deglycosylation. Digestion of the truncated FcyR# with N-glycosidase F (Genzyme,
Boston, MA) was based on the procedure described by Tarentino et al. (27). Samples
were boiled for 3 min in 0.2 M sodium phosphate buffer (pH 8.6) with 10 mM 1,10-
phenanthroline hydrate and varying concentrations of SDS, after which they were incu-
bated with N-glycosidase F for 2 h at 37°C.
Results and Discussion
Isolation of the CHO Cell Line Secreting Truncated FcyR#.
￿
To convert the
FcyR#1, normally an integral membrane protein, to a secreted protein, we
deleted the transmembrane and cytoplasmic domains of the receptor, leaving
the leader sequence and the extracellular domains. When plasmid 3901, which
has a FcyRol cDNA insert encoding signal sequence, extracellular and trans-
membrane domains, and partial cytoplasmic domain, is cleaved with Apa I the
transmembrane and cytoplasmic domains are deleted, leaving a 172-residue
protein with two extracellular Ig-like domains (see Fig. I and Materials and
Methods). The truncated FcTR$ protein is also missing eight amino acids just
outside the membrane. The truncated FcyR# cDNA was inserted in both
orientations into the pcEXV-3 expression vector (9) and transfected along with
pCGcos3neo (28) into the B78H 1 melanoma cell line. After G418 selection,
transfectants were cloned and supernatants were screened by ELISA. Of 19
clones transfected with pFc7R#-19, 9 secreted immunoreactive material, but
none of the 64 clones transfected with pFcyRO-17 were positive. However, the
titer of FcyRo in the supernatant of B1904, one of the better secreting lines,
based on comparison with lysates of the FcyR+ S49.1 cell line, was <5 ng/ml
(Fig. 2), which would make further biochemical studies difficult.QU ET AL .
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FIGURE 1 . Construction of the trun-
cated FcyR# cDNA and the expression
vector . The plasmid containing the
FcyR#1 cDNA insert is illustrated on top
left with the predicted coding regions
(UTfor untranslated region,S for signal
sequence, EC for extracellular domains,
TM for transmembrane domain, and C
for cytoplasmic domain) and the restric-
tion sites for Apa I and Nco 1 . Plasmid
3901 is a FcyR,81 cDNA clone that con-
tains the sequence from 5'UT through
base 1117 within the C region, as the
arrow indicates . The truncated blunt-
endcDNA was purified from agarose gel
and inserted into the Sma I site of
pcEXV-3, which is shown on top right .
The plasmid pFcyR#-19, which has the
sense orientation, is shown on the bot-
tom .
To obtain a higher level of secretion, we transfected pFcyR#-17 and pFc7R#-
19 into a DHFR- CHO cell line along with a dhfr minigene, and selected with
increasing concentrations of methotrexate . This leads to amplification of the
dhfr minigene and flanking transfected FcyR# expression plasmid DNA. The
FcyR#-secreting clones were isolated from mass culture after amplification
resulting in resistance to 2jM methotrexate . The level of secretion of truncated
FcyR# by the D1959 cell line is elevated over 2,000-fold relative to the B1904
melanoma transfectant (Fig . 2) . As expected, none of thepFcYR,3-17-transfected
CHO cells secreted immunoreactive material . Although the slope of the titration
of the intact S49.1 cell FcyR is slightly steeper (possibly due to more efficient
capture of the intact FcyR by the rabbit anti-FcyR antiserum), we estimate, with
a value of 5 X 104 FcyR per S49 .1 cell (results not presented), that the
concentration of truncated FcyR# in medium conditioned by confluent D1959
cells is 2-3 Ag/ml/d .
The much higher level in synthesis of the truncated FcyR# relative to B1904
and S49 .1 should be paralleled by an increase in mRNA level. Cytoplasmic RNA
dot hybridization was performed to investigate the levels of FcyR# mRNA .
Hybridization of nick translation-labeled insert of pFcyR#-17 cDNA to cyto-
plasmic RNA showed a greater than 320-fold higher level of expression of FcyR#
message by the D1959 cell line relative to B1904 and 549.1 cell lines (Fig . 3B) .
The levels of hybridization to cytoplasmicRNA found with a rat metallothionein
cDNA probe were roughly the same for all the cell lines examined (Fig . 3A) .
Identification ofthe Truncated FcyR#.
￿
We examined the total [s5S]methionine-1200
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FIGURE 2. The titration of
FcyRo by mAb 2AG2 . 4 x
10 5 cells of B1902, B1904,
D1717, and D1959 were
seeded in 100-mm plates .
After 24 h, the supernatants
were taken from the plates
and serial threefold dilutions
were assayed . A lysate of
S49.1 cells at 10 7 cells/ml was
used as calibration . (C])B1904 ;
(O) B1902 andD1717, FcyRO
nonsecreting transfectants ;
(O), D1959; (A), S49.1 lysate .
FIGURE 3 .
￿
CytoplasmicRNA
dot hybridization. Lysates at 107 cells/ml were made from
all cell lines except for D1959
in B, for which 106 cells/ml
were used. Serial twofold di-
lutions starting from 1 :4 were
applied onto the nitrocellu-
lose . (A) hybridized with the
metallothionein 1 cDNA in-
sert ; (B) hybridized with the
truncated FcyR# cDNA in-
sert. Using only thecDNA in-
serts as probes was necessary
for these experiments because
the total plasmid hybridized
with mRNA transcribed from
plasmid DNAamplified in the
D1959 cell line .
labeled secretion products from the original CHO DG44 cell line, D1959, and a
companion cell line, D1717, which was transfected with pFcyR#-17 and is also
resistant to 2 gM methotrexate . No difference in the profile of labeled secreted
proteins was detected between the two Fc7R- cell lines DG44 and D1717.
However, the profile (Fig . 4) of labeled secreted proteins from D1959 has a
major additional peak, centered at M, 31,000, which was absent in the DG44
and D1717 cell line labeled secretion products . By densitometry of the autora-
diogram we determined that the 31,000Mr protein comprises 30% of the total
secreted proteins . This is probably an underestimate of the actual amount, since
there is only one methionine in the sequence of the truncated Fc'YR# (1) .
To confirmthat the majorpeak shownin theradiolabeled products is truncatedU
a
0
a
V
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FIGURE 4. Analysis of [s6S]methionine-labeled se-
creted products from transfected cell lines. 106 cells
plated in 60-mm tissue culture dishes for 12 h were
rinsed in PBSand labeled for 6 h in 2 ml of methio-
nine-free medium containing 75 KCi/ml of [ssS]me-
thionine. The supernatant was concentrated and sub-
jected to SDS-PAGE on 10% gel. After autoradiog-
raphy, the film was scanned by a densitometer. The
profile of densitometry is shown with arbitrary ab-
sorbance. (Upper curve) D1959; (lower curve) D1717.
The peak oftruncatedFcryR,6in the profileof D1959
but not in that of D1717 occupies 30% of the total
area. In the insert we show the mobility of the trun-
cated FcyR#(arrow) and molecular weight standards:
myosin (H chain), 200,000; phosphorylase b, 97,400;
BSA, 68,000; OVA, 43,000; and a-chymotrypsino-
gen, 25,700 (Bethesda Research Laboratories, Gaith-
ersburg, MD).
FcyR#, the immunoreactivity oftheproteinsreleased from D1959 was examined
byimmunoblotting after SDS-PAGE. Therabbit anti-FcyRantibodies specifically
bound to the same 31,000 Mr protein (Fig. 5A) in the secretion products of the
D1959 cell line as is seen in the autoradiogram of the [s5S]methionine-labeled
secretion products from D1959 cells in Fig. 3. FcyR from S49.1 cells is consid-
erably larger, with a M,. of60,000 (5). The portion that is deleted of the FcyR#
is 127 amino acids (for the #1 transcript) or 81 amino acids (for the #2 transcript)
and clearly does not account for the difference in Mr seen on SDS-PAGE. The
anomalous electrophoretic mobility of the truncated FcyR# may be due to
carbohydrate.
Characterization of the Truncated FcyR#.
￿
The truncated FcyR# was purified
to homogeneity from the medium conditioned by the D1959 cell line by one
cycle ofaffinity chromatography on IgG2b-Sepharose 4B (Fig. 6, Table I). The
first stepwasa 40-75% saturated ammonium sulfate precipitationofconditioned
medium followed by dialysis. This step functions both to concentrate the FcyR#
and to lower the ionic strength, which leads to tighter binding of the FcyR# to
the IgGmatrix. The affinity column removed>99% ofimmunoreactive material
from the initial concentrated conditioned medium. Recovery oftruncated FcyR#
frbm the concentrated conditioned medium was >85%. The purified protein
shows the same broad electrophoretic mobility on SDS-PAGE (Fig. 7, lane C)
and has the same activity with rabbit anti-FcyR antibodies in immunoblotting1202 A TRUNCATED Fcy RECEPTOR
FIGURE 5 . Immunoblotting analysis of the
truncated FcyRfl. Protein was subjected to 7-
17% SDS-PAGE, transferred to nitrocellulose,
and stained with : (a) mAb6B7C ; (b) rabbit anti-
FcyR IgG ; (c)preimmune rabbit IgG . (A) Con-
centrated serum-free medium from the D1959
cell line ; (B) truncated FcyRf purified on
DHK10.12-Sepharose 4B . Mol wt x 10-"
shown at left .
(Fig . 5B) as the immunoreactive material in the conditioned medium . Based on
amino acid composition with four tryptophan and eight tyrosine residues, the
truncated FcyRo should have an E280 = 33,000 M- ' cm-' (30) . Given an M, of
31,000 for the truncated FcyR#, the yield of purified protein by measuring
OD280 is 2.5 Ag/ml conditioned medium, in good agreement with the ELISA
assay titration .
The external domain of the FcyR has four cysteine residues, two located in
each Ig domain (1, 2) . We performed titrations using Ellman's reagent, 5,5'-
dithio-bis-(2-nitrobenzoic acid) to determine the number offree cysteine residues
and found that truncated FcyR,Q has no free sulfhydryl groups (Table II) .
Alkaline hydrolysis of BSA resulted in 22 .9 free -SH groups per mol, a ratio of
1 .3 titratable -SH per disulfide bond . This value is in agreement with literature
reports (26) for the yield of free sulfhydryls from model disulfide-containing0 10 20 30
FRACTION NUMBER
TABLE I
Purification ofthe Truncated FcyR#from Cell Culture
* Titer is expressed as the reciprocal ofthedilution.
$ Proteins were quantitated by Lowry'smethod (29).
4Comparison of the activity recovered from IgG2baffinity column.
The titer of cell culture supernatant is the average value of several separate assays and was
determined, in any one set of assays, by the titer resulting in 50% maximum OD4yo. The total
activity of the concentrated supernatant was always somewhat higher (50-100%) than that of the
starting cell culture supernatant.
TABLE II
Titration of TruncatedFcyR# Sulfhydryl Groups with Ellman's Reagent
* There is one free sulfidegroupin bovine albumin (31).
Since titrationwith Ellman'sreagentofalbuminwithouthydroxidecleavage wasnegative,
we assume thealbumin preparation wasdimerized.
4 Calculated from this experiment by dividing experimental -SH/S-S for albumininto the
-SH/protein obtained forthetruncated FcyR#.
peptides. Alkaline hydrolysis of the truncated FcyR,B gave 2.51 -SH per mol.
When corrected for the yield of -SH/S-S, a value of 1.91 S-S bonds/mol of
truncated FcyR# was obtained. Reverse-phase HPLC profiles oftryptic digests
of the truncated FcyR# with and without reduction were also compatible with
QU ET AL. 1203
0.28
0.21 FIGURE 6. Purification of thetruncated FcyR#. 150 ml of _
E D1959 supernatant wasconcentrated to 2ml by ammonium
0 sulfate precipitation, dialyzed versus 10 mM sodium phos- m
0.14 phate buffer, pH 7.5, and loaded (arrow 1) onto the
DHK10.12-Sepharose4B column (3 ml of bedvolume). The 0 0 column was washed with 50 mM NaCl and the truncated
Fc,yR# was eluted (arrow 2) with 0.1 M acetate buffer (pH
0.07 4.0), 0.5 M NaCl.
0.00
Step of purification Volume
ml
Titerper
ml
Total
activity
(titer)
Total
proteins
mg
Specific
activity
titer/mg
Recovery
of activity'
Cell culture supernatant 50 7.0 x 1034 3.5 x 105
Concentrated supernatant 1.0 3.8 x 105 3.8 x 105 113 3.4 x 105 100
Post affinity supernatant 6 1.7 x 102 1.0 x 105 60 1.7 x 10'
Acid eluant 4.5 7.3 x 104 3.3 x 105 0.37 8.9 x 105 86.8
Protein OD4, s/M -SH/protein Number of
S-S bonds -SH/S-S
Albumin 0 0* 17.5$ -
Albumin, alkali treated 3.25 x 105 22.9 - 1.31
Truncated Fc-yR13 0 0 1.924 -
Truncated FcyR,6, alkali treated 0.35 x 105 2.51 - NA1204
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FIGURE 7 . N-glycosidase F digestion of truncated
FcyR#. 25 Pg of truncated FcyR# was digested with
0.25U N-glycosidase F, and then subjected to SDS-
PAGE on a 12.5% gel . (Lane A) Molecular weight
standards; (lane B) 25 fag of native truncated FcyR#
digested with 1 .5 UN-glycosidase F ; (lane C) purified
truncated FcyR# without digestion; (lanes D-G) trun-
cated FcyR# boiled for 3 min with either 0.5% (D),
0.1% (E), 0.02% (F), or no (G) SDSbefore digestion .
the presence of intrachain disulfide bonds (data not shown) . Like many other
members of the Ig gene superfamily, the cysteines form intramolecular linkages
in the FcyR# and, therefore, the two repeats of the extracellular domain form
two loops, although these loops are much shorter (42-45 amino acids) than in
other members of the family .
The predicted amino acid sequence ofmoFcyR (both a and # genes) has four
potential sites for N-linked glycosylation (1, 2) . Limited endoglycosidase F diges-
tion of FcyR isolated fromJ774 after a short pulse with [s5S]methionine resulted
in five intermediates, consistent with four glycosylation sites (32) . The truncated
FcyR# purified by affinity chromatography on IgG2b-Sepharose 4B shows the
same broad electrophoretic mobility as the intact FcyR, suggesting it is also
glycosylated . Digestion of the truncated FcyR# with N-glycosidase F confirmed
the presence of carbohydrate (Fig. 7), and resulted in a deglycosylated core of
19,000 M,., which is in agreement with the predicted length of the peptide
backbone of the truncated FcyR#, 176 amino acids. The protein could be
deglycosylated only after partial denaturation, either by SDS or by boiling ; intact
truncated FcyR was very poorly digested by N-glycosidase F. The 12,000 M,
difference between the glycosylated and deglycosylated truncated FcyR# is
somewhat less than that found forJ774 Fc7R (60,000 versus 37,000 M,).
The Biological Activity of the Truncated FcyR#.
￿
The purification of truncated
FcyR# by affinity chromatography on IgG2b-Sepharose demonstrated the reten-
tion of specificity of the recombinant truncated receptor . To determine the
isotype specificity of the truncated Fc7R#, we examined the binding of ['25I]-
DNP2oBSA-anti-DNP mAb complexes to truncated FcyR# adsorbed to micro-
titer plates . Labeled immune complexes formed from IgGI anti-DNP mAbs
(U7.6 and DHK 109.3), IgG2a (U7.6), and IgG2b (DHK10 .12) bound to the
truncated FcyR#(Fig . 8) . The avidity ofthe truncatedFcyR#forIgG 1 antibody-
antigen complexes was significantly stronger than that for IgG2a and IgG2b
complexes . However, no binding was observed for the IgG2b anti-DNP-mAb
U 12.5, which may be due to a low avidity of U12 .5 for DNP. No binding was
seen for the MPC-11 control (Fig. 8D) . From these results, we conclude that the
affinity of the truncated FcyR# for murine IgG isotypes as immune complexes
is IgGl>IgG2b=IgG2a .
Using the same assay for binding of immune complexes, we examined the
effect of pH on truncated FcyR# activity using the IgGl anti-DNP mAb U7 .6 .
There was more binding of the labeled DNP2oBSA in immune complexes at
more acid pH (Fig . 9) . This differs from a previous report by Mellman and
Unkeless (5) in which the binding of labeled intact FcyR, isolated from macro-Z-Q I x
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FIGURE 9. Binding by truncated FcyRo of
IgGI U7.6 immune complexes as a function of
pH . Citrate-phosphate buffer was used for pH
3-5, sodium phosphatebuffer forpH 6-8, and
glycine buffer for pH 9-10 (33). All buffers
were adjusted to 10 mM and contained 0.1 M
NaCl. The immune complex was prepared
as described in Fig. 8 with a final concentra-
tion of 5 fag/ml U7.6 and 0.5 ug/ml ['25I1-
DNP2oBSA. The immune complex was diluted
10-fold with the different buffers before trans-
fer into the truncated FcryRo-coated wells and
control wells. (0) truncated FcyR#-coated
wells; (O) control wells.
phages, to rabbit immune complexes was examined, and found to decrease
sharply at pH 5.0. The failure of FcyR internalized with immune complexes to
recycleto the cell surface, but rather to be digested in thelysosomal compartment
(34, 35), is more easily explained by the failure ofthe receptor-ligand complex
to dissociate at acid pH. The intact FcyR in the absence ofdetergent exists in a
protein micelle, due to aggregation ofthe hydrophobic transmembrane domains.
It is possible that this micelle at low pH dissociates, resulting in a loss of
cooperative binding necessary for binding to the immune complexes. This
consideration did not apply in the present experiments in which the truncated
FcyR# was adsorbed onto the plastic surface.
Mappingofthe Epitope Recognized by mAb 6B7C.
￿
6B7C isan anti-moFcyR mAb
that effectively reacts with FcyR from all cells after SDS-PAGE and transfer to
nitrocellulose. However, it reacts variably with FcyR on viable FcyR+ cells. For
example, mAb 6B7C binds to the surface of LPS-activated B cells andJ774 cells,
but not to primary macrophages or B cells (36). When we attempted to detect
thesecretedFcyR#usingmAb 6B7C, weweresurprised to find that thisantibody
did not recognize the truncated FcyR# on immunoblots (Fig. 5). Furthermore,
although in the ELISA assay, mAb 6B7C bound to the FcyR# from detergent
lysates of S49.1 cells as well as mAb 2AG2 did, it failed to react with the
truncated FcyR# (Fig. 10A).
Since the truncated FcyR# is missing the 8 amino acids nearest the membrane
of the external domain, the epitope may be in the deleted peptide. Alternatively,
it is also possible that the FcyR# made in CHO cells is different by virtue of
altered glycosylation, or that the truncated FcyR#, due toaltered conformation,
has lost the 6B7C epitope. To test these possibilities, we synthesized the peptide
ITVQGPKSSRSLPVL (amino acids 169-183 of the FcyR#) and tested this
peptide, coupled to OVA, as a ligand. As can be seen in Fig. 10B, 6B7C bound
to ITVQGPKSSRSLPVL-OVA-coated wells in a dose-dependent fashion, but
there was no binding of either 6B7C to OVA-coated wells, or 2AG2 to either
OVA- or ITVQGPKSSRSLPVL-OVA-coated wells. These results indicate that
the epitope recognized by mAb 6B7C is certainly within amino acids 169-183
and that crucial residues for the 6B7C epitope lie after residue 173 (the terminus
of the truncated FcyR#). Furthermore, since the predicted FcyRa and FcyR#
protein sequences are quite different in this region, mAb 6B7C is a FcyR#-
specific probe, which we have confirmed in preliminary experiments (Schreiber,E c
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Identification of theepitope of FcyR,B recognized by mAb 6B7C. (A) Reactivity
of mAbs 6B7C (*and A) and 2AG2 (O and A) with conditioned medium from the D1959cell
line (" and O) and a NP-40 lysate (107 cells/ml) of S49.1 cells (A and p). (B) Reactivity of
mAbs 2AG2 (0 and A) and 6B7C (O andA) with ITVQGPKSSRSLPVL-OVA(9 andO) and
OVA (A and A). Serial dilutions of OVA or ITVQGPKSSRSLPVL-OVA conjugate coating
the wellsbegan at 400 wg/ml.
R., andJ. Unkeless, unpublished results). The location of the 6B7C epitope, just
at the plasma membrane, suggests that the epitope may be masked, perhaps by
other proteins or cell surface constituents, in the cells bearing FcyR,Q that fail to
bind mAb 6B7C .
We have isolated a recombinant secreted FcyR# molecule by deletion of the
transmembrane and cytoplasmic domains encoding sequence from a FcyR#1
cDNA clone, and insertion of the truncated cDNA into a eukaryotic expression
vector, pcEXV-3 . To express and amplify the production ofthe truncated Fc'YR#
molecule, we transfected the truncated cDNA plasmid into a dihydrofolate
reductase-minus CHO cell line along with a dhfr minigene, and amplified the
gene products with methotrexate. The resulting cell line secretes 2-3'Ug/ml/24
h of truncated FcyR#, which can be readily purified by affinity chromatography
on IgG-Sepharose . The truncated FcyR# has a Mr of 31-33,000 on SDS-PAGE
and is glycosylated. N-glycosidase F cleavage reduces the Mr to 19,000, consistent
with the size of the truncated product, 176 amino acid residues. There are two
disulfide bonds in the protein. Binding of immune complexes formed between
DNP20BSA and anti-DNP mAbs reveals better binding of IgGI aggregates than
that of IgG2b and IgG2a aggregates. The binding of the immune complexes was
somewhat better at more acidic pH, in contrast to previous experiments with
binding of purified FcyR to immune complex-coated beads.
We were surprised to observe that the truncated FcyR# did not react with the
anti-FcyR mAb 6B7C. Previous work had shown that 6B7C reacts with Fc-YR on
immunoblots, fails to bind to the surface of resting B cells and peritoneal
macrophages, but does bind to macrophage cell lines and LPS-stimulated B cells.
We show, by binding of mAb 6B7C to a peptide conjugate, that the 6B7C1208
￿
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epitope lies within residues 169-183 of the intact FcyR#, which is just outside
the plasma membrane.
The availability of the truncated FcyR# in microgram quantities should
facilitate further analysis of structure and function ofthese receptors.
We gratefully acknowledge the expert technical assistanceof Ivette V. Tzannetakis.
Receivedfor publication 19 October 1987.
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